Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide
- 31 December 1993
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (2), 209-217
- https://doi.org/10.1016/0959-8049(93)90178-i
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: Results of a double blind multicentre clinical trialEuropean Journal of Cancer and Clinical Oncology, 1988
- Serum prolactin levels in women with breast cancer and their relationship to survivalEuropean Journal of Cancer and Clinical Oncology, 1986
- Intrinsic and extrinsic factors in estrogen action in human breast cancer: Role of polamines and pituitary factorsJournal of Steroid Biochemistry, 1986
- Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancerInternational Journal of Cancer, 1984
- Growth Hormone Binding to Cultured Human Breast Cancer Cells*Journal of Clinical Endocrinology & Metabolism, 1984
- Prognostic significance of serum prolactin levels in advanced breast cancerBritish Journal of Cancer, 1983
- Prolactin and Growth Hormone: Specialists on One Hand and Mutual Mimics on the OtherPerspectives in Biology and Medicine, 1982
- Transsphenoidal hypophysectomy in breast cancer.Evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth.Cancer, 1979
- Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.BMJ, 1977
- Clinical trial of 2-Br-α-ergocryptine (CB154) in advanced breast cancerEuropean Journal of Cancer (1965), 1972